Blockchain Registration Transaction Record
Bora Buys MacroGenics' GMP Ops for $122.5M, Boosts US Biologics Capacity
Bora Pharmaceuticals acquires MacroGenics' GMP manufacturing for $122.5M, creating a 20,000L US biologics platform. Key for biotech CDMO needs.
This acquisition matters because it strengthens US-based biologics manufacturing capacity, reducing reliance on offshore production. For biotech and pharma companies, it offers a proven, FDA-inspected platform for developing and commercializing biologics and biosimilars, potentially lowering supply chain risks and accelerating time to market. As regulatory dynamics evolve, having a domestic manufacturing partner becomes crucial for ensuring stable supply and compliance.
| Blockchain | Details |
|---|---|
| Contract Address | 0xeA2912a8DA1CD48401b10cB283585874d98098F4 |
| Transaction ID | 0x5a7d7580c50d36f1ff23520a067761f8f5b3e87ab52a2b45bd9bdf8767ef6861 |
| Account | 0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20 |
| Chain | polygon-main |
| NewsRamp Digital Fingerprint | tallKMRh-66299f4cb5bda12a6689194f9108ac62 |